Great Lakes Retirement Inc. Purchases 11,907 Shares of Merck & Co., Inc. $MRK

Key Points

• Great Lakes Retirement Inc. acquired 11,907 Merck shares worth approximately $1.74 million during the third quarter, while institutional investors collectively own 76.07% of MRK.
• Merck’s oncology pipeline remains a key catalyst: KEYTRUDA reduced progression or death risk by 43% in a Phase 3 endometrial-cancer trial, while the Moderna-partnered melanoma vaccine reduced recurrence risk by 42%.
• Despite generally bullish analyst ratings and a $153.12 average price target, investors face risks from weaker Gardasil demand, declining earnings estimates, difficult comparisons and patent exposure; insiders have also sold nearly $30 million of stock over the past 90 days.

Great Lakes Retirement Inc. acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 11,907 shares of the company's stock, valued at approximately $1,740,000.

Other institutional investors have also added to or reduced their stakes in the company. Bullseye Investment Management LLC bought a new stake in Merck & Co., Inc. during the 2nd quarter valued at approximately $27,000. Curry Webb Wealth Management LLC bought a new position in shares of Merck & Co., Inc. in the 3rd quarter worth approximately $29,000. Horizons Wealth Management purchased a new position in shares of Merck & Co., Inc. in the 3rd quarter valued at approximately $30,000. Graney & King LLC lifted its stake in shares of Merck & Co., Inc. by 400.0% in the 2nd quarter. Graney & King LLC now owns 250 shares of the company's stock valued at $32,000 after purchasing an additional 200 shares during the period. Finally, Montgomery Financial Services LLC bought a new stake in shares of Merck & Co., Inc. during the second quarter valued at approximately $41,000. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s KEYTRUDA reduced the risk of disease progression or death by 43% in a Phase 3 endometrial-cancer trial. The result strengthens the company’s oncology franchise and could support future label expansion and revenue growth. Merck's KEYTRUDA Cuts Progression Risk By 43% In Phase 3 Endometrial Cancer Trial
• Positive Sentiment: Additional oncology readouts, including positive results from the Moderna-partnered melanoma vaccine and other cancer treatments, are providing fresh support for Merck’s pipeline and long-term growth prospects. Merck Gains Fresh Oncology Backing As Valuation Debate Heats Up
• Positive Sentiment: Broker commentary remains broadly constructive, with Barclays forecasting significant appreciation potential and other analysts highlighting KEYTRUDA demand and new-drug growth ahead of the earnings release. Barclays Forecasts Strong Price Appreciation for Merck
• Neutral Sentiment: Merck is scheduled to report third-quarter results before the market opens on October 29. Investors are focused on KEYTRUDA sales, full-year guidance and management’s outlook for the pipeline. Dear Merck Stock Fans, Mark Your Calendars for October 29
• Neutral Sentiment: The Moderna-Merck melanoma vaccine cut recurrence risk by 42% in a Phase 3 trial, but the outcome reportedly fell short of investor expectations, limiting its immediate effect on MRK. Merck and Moderna's Cancer Vaccine Worked
• Negative Sentiment: Pre-earnings concerns include difficult year-over-year comparisons, declining earnings estimates, weaker Gardasil demand and looming patent exposure. These factors could offset strong KEYTRUDA performance and increase volatility around the report. Is Merck Stock a Buy, Sell or Hold Ahead of Q3 Earnings?

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP David Maraldo sold 18,706 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the transaction, the executive vice president directly owned 18,212 shares of the company's stock, valued at $2,344,248.64. This represents a 50.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Jennifer Zachary sold 80,315 shares of the firm's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the transaction, the executive vice president owned 45,509 shares in the company, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is owned by corporate insiders.

Merck & Co., Inc. Price Performance

MRK opened at $141.03 on Thursday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The stock has a market capitalization of $347.95 billion, a P/E ratio of 112.83, a P/E/G ratio of 6.74 and a beta of 0.21. The company's 50-day simple moving average is $147.01 and its two-hundred day simple moving average is $126.31. Merck & Co., Inc. has a 52-week low of $82.01 and a 52-week high of $156.92.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business's quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts predict that Merck & Co., Inc. will post 2.64 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on MRK shares. Wolfe Research lifted their price target on Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 25th. Argus raised their price objective on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the company a "buy" rating in a research note on Tuesday, August 25th. JPMorgan Chase & Co. lifted their target price on shares of Merck & Co., Inc. from $150.00 to $165.00 and gave the stock an "overweight" rating in a report on Monday, October 5th. TD Cowen increased their price target on shares of Merck & Co., Inc. from $137.00 to $155.00 and gave the company a "hold" rating in a report on Wednesday, September 23rd. Finally, Jefferies Financial Group raised their price target on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the company a "buy" rating in a research report on Thursday, August 20th. Seventeen research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $153.12.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck's principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.